Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau5907. doi: 10.1126/scitranslmed.aau5907.

PMID:
31270272
2.

CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.

Sauter CS, Senechal B, Rivière I, Ni A, Bernal Y, Wang X, Purdon T, Hall M, Singh AN, Szenes VZ, Yoo S, Dogan A, Wang Y, Moskowitz CH, Giralt S, Matasar MJ, Perales MA, Curran KJ, Park J, Sadelain M, Brentjens RJ.

Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.

PMID:
31262783
3.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 May 15. doi: 10.1038/s41409-019-0451-2. [Epub ahead of print]

PMID:
31092900
4.

Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.

Drent E, Poels R, Ruiter R, van de Donk NWCJ, Zweegman S, Yuan H, de Bruijn J, Sadelain M, Lokhorst HM, Groen RWJ, Mutis T, Themeli M.

Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.

PMID:
30979735
5.

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Palomba ML, Halton E, Bernal Y, van Leeuwen DG, Sadelain M, Park JH, Brentjens RJ.

JCI Insight. 2019 Apr 2;5. pii: 122627. doi: 10.1172/jci.insight.122627.

6.

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, Li Z, Cunanan KM, Huse M, Hendrickson RC, Wang X, Rivière I, Sadelain M.

Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.

7.

Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.

Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M.

Nat Med. 2019 Mar;25(3):530. doi: 10.1038/s41591-019-0360-3.

PMID:
30692700
8.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
9.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency.

Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, Dobrin A, Cabriolu A, Hamieh M, Sadelain M.

Nat Med. 2019 Jan;25(1):82-88. doi: 10.1038/s41591-018-0290-5. Epub 2018 Dec 17. Erratum in: Nat Med. 2019 Mar;25(3):530.

10.

Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.

DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M.

Mol Ther. 2018 Nov 7;26(11):2542-2552. doi: 10.1016/j.ymthe.2018.09.008. Epub 2018 Sep 13.

PMID:
30415658
11.

Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Cornetta K, Duffy L, Feldman SA, Mackall CL, Davila ML, Curran KJ, Junghans RP, Tang JY, Kochenderfer JN, O'Cearbhaill R, Archer G, Kiem HP, Shah NN, Delbrook C, Kaplan R, Brentjens RJ, Rivière I, Sadelain M, Rosenberg SA.

Mol Ther Methods Clin Dev. 2018 Aug 17;10:371-378. doi: 10.1016/j.omtm.2018.08.006. eCollection 2018 Sep 21.

12.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 Sep;103(9):1577. doi: 10.3324/haematol.2018.199414. No abstract available.

13.

Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia.

Hamieh M, Sadelain M.

Trends Mol Med. 2018 Sep;24(9):729-731. doi: 10.1016/j.molmed.2018.06.007. Epub 2018 Jul 4.

PMID:
30149852
14.

Chimeric Antigen Receptor Therapy.

June CH, Sadelain M.

N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169. Review. No abstract available.

PMID:
29972754
15.

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.

Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.

Leukemia. 2019 Jan;33(1):64-74. doi: 10.1038/s41375-018-0180-3. Epub 2018 Jun 26.

16.

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Geyer MB, Rivière I, Sénéchal B, Wang X, Wang Y, Purdon TJ, Hsu M, Devlin SM, Halton E, Lamanna N, Rademaker J, Sadelain M, Brentjens RJ, Park JH.

Mol Ther. 2018 Aug 1;26(8):1896-1905. doi: 10.1016/j.ymthe.2018.05.018. Epub 2018 Jun 15.

17.

Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.

Krebs S, Ahad A, Carter LM, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, Larson SM, Weber WA.

J Nucl Med. 2018 Dec;59(12):1894-1900. doi: 10.2967/jnumed.118.208041. Epub 2018 Jun 14.

18.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

19.

CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.

Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M.

Nat Med. 2018 Jun;24(6):731-738. doi: 10.1038/s41591-018-0041-7. Epub 2018 May 28.

20.

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.

Park JH, Romero FA, Taur Y, Sadelain M, Brentjens RJ, Hohl TM, Seo SK.

Clin Infect Dis. 2018 Aug 1;67(4):533-540. doi: 10.1093/cid/ciy152.

21.

Gene Therapy and Genome Editing.

Boulad F, Mansilla-Soto J, Cabriolu A, Rivière I, Sadelain M.

Hematol Oncol Clin North Am. 2018 Apr;32(2):329-342. doi: 10.1016/j.hoc.2017.11.007. Epub 2018 Jan 9. Review. Erratum in: Hematol Oncol Clin North Am. 2018 Jun;32(3):xiii.

PMID:
29458735
22.

Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

Perales MA, Kebriaei P, Kean LS, Sadelain M.

Biol Blood Marrow Transplant. 2018 Mar;24(3S):S15-S19. doi: 10.1016/j.bbmt.2017.12.789. Review.

23.

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results.

Boulad F, Shore T, van Besien K, Minniti C, Barbu-Stevanovic M, Fedus SW, Perna F, Greenberg J, Guarneri D, Nandi V, Mauguen A, Yazdanbakhsh K, Sadelain M, Shi PA.

Haematologica. 2018 May;103(5):770-777. doi: 10.3324/haematol.2017.187047. Epub 2018 Feb 1. Erratum in: Haematologica. 2018 Sep;103(9):1577.

24.

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M.

N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

25.

Posttransplant chimeric antigen receptor therapy.

Smith M, Zakrzewski J, James S, Sadelain M.

Blood. 2018 Mar 8;131(10):1045-1052. doi: 10.1182/blood-2017-08-752121. Epub 2018 Jan 22. Review.

26.

Mechanogenetics for the remote and noninvasive control of cancer immunotherapy.

Pan Y, Yoon S, Sun J, Huang Z, Lee C, Allen M, Wu Y, Chang YJ, Sadelain M, Shung KK, Chien S, Wang Y.

Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):992-997. doi: 10.1073/pnas.1714900115. Epub 2018 Jan 17.

27.

Gene therapy comes of age.

Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M.

Science. 2018 Jan 12;359(6372). pii: eaan4672. doi: 10.1126/science.aan4672. Review.

PMID:
29326244
28.

CD19 CAR T Cells.

Sadelain M.

Cell. 2017 Dec 14;171(7):1471. doi: 10.1016/j.cell.2017.12.002.

29.

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Oncotarget. 2017 Sep 12;8(44):77872-77882. doi: 10.18632/oncotarget.20845. eCollection 2017 Sep 29.

30.

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.

Geyer MB, Manjunath SH, Evans AG, Park JH, Davila ML, Cutler CS, Wang X, Wang Y, Senechal B, Rivière I, Sadelain M, Liesveld JL, Brentjens RJ.

Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18. No abstract available.

31.

Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.

Perales MA, Kebriaei P, Kean LS, Sadelain M.

Biol Blood Marrow Transplant. 2018 Jan;24(1):27-31. doi: 10.1016/j.bbmt.2017.10.017. Epub 2017 Oct 13. Review.

32.

Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML.

Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson RC, Brennan CW, Sadelain M.

Cancer Cell. 2017 Oct 9;32(4):506-519.e5. doi: 10.1016/j.ccell.2017.09.004.

33.

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.

Perna F, Sadelain M.

Transl Cancer Res. 2016 Aug;5(Suppl 2):S221-S225. doi: 10.21037/tcr.2016.08.15. No abstract available.

34.

Therapeutic T cell engineering.

Sadelain M, Rivière I, Riddell S.

Nature. 2017 May 24;545(7655):423-431. doi: 10.1038/nature22395. Review.

35.

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Rivière I, Sadelain M.

Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26. Review.

36.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.

Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, Odak A, Gönen M, Sadelain M.

Nature. 2017 Mar 2;543(7643):113-117. doi: 10.1038/nature21405. Epub 2017 Feb 22.

37.

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M.

Mol Ther Oncolytics. 2017 Jan 11;3:1-9. doi: 10.1038/mto.2016.23. eCollection 2016.

38.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR.

Nat Med. 2017 Feb;23(2):242-249. doi: 10.1038/nm.4258. Epub 2017 Jan 9.

39.

LiPS-A3S, a human genomic site for robust expression of inserted transgenes.

Kotini AG, Sadelain M, Papapetrou EP.

Mol Ther Nucleic Acids. 2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.99.

40.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH.

J Clin Invest. 2016 Nov 1;126(11):4262-4272. doi: 10.1172/JCI84813. Epub 2016 Oct 17.

41.

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.

J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.

42.

Chimeric antigen receptors: driving immunology towards synthetic biology.

Sadelain M.

Curr Opin Immunol. 2016 Aug;41:68-76. doi: 10.1016/j.coi.2016.06.004. Epub 2016 Jun 30. Review.

43.

Biology and clinical application of CAR T cells for B cell malignancies.

Davila ML, Sadelain M.

Int J Hematol. 2016 Jul;104(1):6-17. doi: 10.1007/s12185-016-2039-6. Epub 2016 Jun 4. Review.

44.

Tales of Antigen Evasion from CAR Therapy.

Sadelain M.

Cancer Immunol Res. 2016 Jun;4(6):473. doi: 10.1158/2326-6066.CIR-16-0089.

45.

Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ.

Clin Exp Immunol. 2016 Nov;186(2):249-265. doi: 10.1111/cei.12816. Epub 2016 Aug 31.

46.

Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects.

Mansilla-Soto J, Riviere I, Boulad F, Sadelain M.

Hum Gene Ther. 2016 Apr;27(4):295-304. doi: 10.1089/hum.2016.037. Review.

47.

Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response.

Themeli M, Sadelain M.

Trends Mol Med. 2016 Apr;22(4):271-273. doi: 10.1016/j.molmed.2016.02.009. Epub 2016 Mar 10.

48.

A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome Editing.

Sadelain M.

Mol Ther. 2016 Mar;24(3):407-8. doi: 10.1038/mt.2016.25. No abstract available.

49.

Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene.

Kotini AG, de Stanchina E, Themeli M, Sadelain M, Papapetrou EP.

Mol Ther Nucleic Acids. 2016 Feb 2;5:e284. doi: 10.1038/mtna.2015.57.

50.

The quest for spatio-temporal control of CAR T cells.

Sun J, Sadelain M.

Cell Res. 2015 Dec;25(12):1281-2. doi: 10.1038/cr.2015.131. Epub 2015 Nov 17.

Supplemental Content

Loading ...
Support Center